The Advisory Committee on Immunization Practices (ACIP) has revised its interval recommendations for the pneumococcal polysaccharide vaccine (PPSV23) and pneumococcal conjugate vaccine (PCV13) in ...

A cohort study found that influenza and 23-valent pneumococcal polysaccharide vaccines (PPSV23) can reduce the risk of chronic obstructive pulmonary disease (COPD)- and pneumonia-related ...

The PPSV23 vaccine has been shown to have efficacy rates of 60% to 70% in helping to prevent invasive disease caused by serotypes covered by the vaccine. PCV15 and PCV20 are still too new to have good ...

study confirms shingles vaccine effective in elderly with ESRD ACIP changed the recommended interval between PCV13 followed by PPSV23 (PCV13-PPSV23 sequence) from 6-12 months to ≥1 year for ...

Please provide your email address to receive an email when new articles are posted on . Although vaccines have reduced the burden of pneumococcal disease, pneumonia due to Streptococcus pneumoniae and ...

(HealthDay News) – A model shows that replacing the current 23-valent pneumococcal polysaccharide vaccine (PPSV23) with the 13-valent pneumococcal conjugate vaccine (PCV13) might prevent more ...

September 7, 2010 — Guidelines have been updated for use of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) in adults, according to a report in the September 3 issue of MMWR. Morbidity and ...

Pneumococcal vaccines, like PCV13 and PPSV23, protect against serious infections caused by Streptococcus pneumoniae bacteria, which can affect children, older adults, and those with chronic health ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...